According to Agenus 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.27876. At the end of 2023 the company had a P/S ratio of 5.62.
Year | P/S ratio | Change |
---|---|---|
2023 | 5.62 | -24.72% |
2022 | 7.46 | 166.81% |
2021 | 2.80 | -60.45% |
2020 | 7.07 | 89.19% |
2019 | 3.74 | -51.85% |
2018 | 7.76 | 1.93% |
2017 | 7.62 | -52.1% |
2016 | 15.9 | 0.62% |
2015 | 15.8 | -55.71% |
2014 | 35.7 | 13.24% |
2013 | 31.5 | 398.66% |
2012 | 6.32 | -59.42% |
2011 | 15.6 | -53.59% |
2010 | 33.6 | 94.8% |
2009 | 17.2 | 43.57% |
2008 | 12.0 | -31.32% |
2007 | 17.5 | -85.59% |
2006 | 121 | -64.81% |
2005 | 344 | -21.89% |
2004 | 441 | 337.83% |
2003 | 101 | 1.34% |
2002 | 99.4 | -4.86% |
2001 | 104 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 4.03 | -5.84% | ๐บ๐ธ USA |
![]() Merck MRK | 4.54 | 6.08% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 2.69 | -37.18% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 2.13 | -50.31% | ๐ฌ๐ง UK |
![]() Celldex Therapeutics CLDX | 406 | 9,398.06% | ๐บ๐ธ USA |